Antioxidant Effect of a New Calcium Antagonist, Azelnidipine, in Cultured Human Arterial Endothelial Cells
Authors:
- 1 April 2004
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 32 (2) , 170-175
Abstract
Azelnidipine is a novel dihydropyridine-type calcium antagonist with long-acting anti-hypertensive action and a low reported incidence of tachycardia. We aimed to evaluate its antioxidant activity in cultured human arterial endothelial cells under oxidative stress. Endothelial cells were exposed to 1 mM H2O2 and treated with 100 μM α-tocopherol, 1 nM, 10 nM or 100 nM azelnidipine, 100 nM nifedipine or 100 nM amlodipine. After 3 h, the cell number and level of lipid peroxidation were evaluated by measuring the total protein and 8-iso-PGF2α concentrations, respectively. The total protein concentration was similar with each treatment. Inhibition of 8-iso-PGF2α was greatest with 10 nM azelnidipine (compared with the other drugs); the difference between 10 nM and 100 nM azelnidipine was not significant. We conclude that azelnidipine has a potent antioxidative effect that could be of significant clinical benefit when combined with its long-lasting anti-hypertensive action and low incidence of tachycardia.Keywords
This publication has 23 references indexed in Scilit:
- Inhibition of Excessive Neuronal Apoptosis by the Calcium Antagonist Amlodipine and Antioxidants in Cerebellar Granule CellsJournal of Neurochemistry, 1999
- The generation and actions of isoprostanesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1997
- Local Amplification of Platelet Function by 8-Epi Prostaglandin F2α Is Not Mediated by Thromboxane Receptor IsoformsJournal of Biological Chemistry, 1996
- In Vitro Antioxidant Activity of Calcium Antagonists against LDL Oxidation Compared with α-TocopherolBiochemical and Biophysical Research Communications, 1994
- Formation of non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro.Journal of Clinical Investigation, 1994
- Protective effects of calcium antagonists in different organs and tissuesAmerican Heart Journal, 1993
- Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors.Journal of Clinical Investigation, 1992
- A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism.Proceedings of the National Academy of Sciences, 1990
- Mechanism of antiatherogenic action of calcium antagonistsAtherosclerosis, 1989
- Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker.The Japanese Journal of Pharmacology, 1989